Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Utility of Liquid Biopsy as a Tool to Assess the Evolution of Brigatinib Treated Patients With Non-small Cell Lung Cancer With EML4-ALK Translocation: an Exploratory Study

NCT04223596 is registered in ClinicalTrials.gov with Fundación GECP as lead sponsor.

NCT NCT04223596
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04223596 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Utility of Liquid Biopsy as a Tool to Assess the Evolution of Brigatinib Treated Patients With Non-small Cell Lung Cancer With EML4-ALK Translocation: an Exploratory Study
Lead sponsor
Fundación GECP
Phase
Phase 2
Overall status
Active, not recruiting
Start date
May 4, 2020
Completion date
December 30, 2026
Enrollment
33 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

lung cancer, nsclc, nsclc stage iiib, nsclc stage iv